Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...

Ocugen, Inc. (OCGN) has two upcoming data readouts expected in 2024, both of which could drive shareholder value higher. This would be regarding the use of OCU-410 and OCU-410ST, which are being ...